CN102712633B - 黄病毒科病毒的抑制剂 - Google Patents

黄病毒科病毒的抑制剂 Download PDF

Info

Publication number
CN102712633B
CN102712633B CN201180005975.8A CN201180005975A CN102712633B CN 102712633 B CN102712633 B CN 102712633B CN 201180005975 A CN201180005975 A CN 201180005975A CN 102712633 B CN102712633 B CN 102712633B
Authority
CN
China
Prior art keywords
optionally substituted
another aspect
het
compound
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180005975.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102712633A (zh
Inventor
E·卡纳勒斯
M·O·H·科拉克
S·E·拉泽维斯
W·勒维
P·A·莫加纳利
W·J·沃特金斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43538203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102712633(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CN102712633A publication Critical patent/CN102712633A/zh
Application granted granted Critical
Publication of CN102712633B publication Critical patent/CN102712633B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201180005975.8A 2010-01-15 2011-01-14 黄病毒科病毒的抑制剂 Active CN102712633B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29557610P 2010-01-15 2010-01-15
US61/295,576 2010-01-15
US35348110P 2010-06-10 2010-06-10
US61/353,481 2010-06-10
PCT/US2011/021335 WO2011088345A1 (en) 2010-01-15 2011-01-14 Inhibitors of flaviviridae viruses

Publications (2)

Publication Number Publication Date
CN102712633A CN102712633A (zh) 2012-10-03
CN102712633B true CN102712633B (zh) 2015-07-29

Family

ID=43538203

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180005975.8A Active CN102712633B (zh) 2010-01-15 2011-01-14 黄病毒科病毒的抑制剂

Country Status (27)

Country Link
US (2) US8513298B2 (enExample)
EP (2) EP2523950B1 (enExample)
JP (2) JP5868872B2 (enExample)
KR (1) KR101727776B1 (enExample)
CN (1) CN102712633B (enExample)
AP (1) AP3576A (enExample)
AR (1) AR080001A1 (enExample)
AU (1) AU2011205744B2 (enExample)
BR (1) BR112012017382A2 (enExample)
CA (1) CA2785567C (enExample)
CL (1) CL2012001960A1 (enExample)
CR (1) CR20120417A (enExample)
EA (1) EA021196B1 (enExample)
EC (1) ECSP12012104A (enExample)
ES (1) ES2626150T3 (enExample)
IL (1) IL220545B (enExample)
MX (1) MX2012008211A (enExample)
NZ (1) NZ600817A (enExample)
PE (1) PE20130281A1 (enExample)
PL (1) PL2523950T3 (enExample)
PT (1) PT2523950T (enExample)
SG (2) SG10201500298PA (enExample)
SI (1) SI2523950T1 (enExample)
TW (1) TWI491609B (enExample)
UY (1) UY33183A (enExample)
WO (1) WO2011088345A1 (enExample)
ZA (1) ZA201205248B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120051022A (ko) * 2009-07-21 2012-05-21 길리애드 사이언시즈, 인코포레이티드 플라비비리데 바이러스의억제제
CA2771124C (en) 2009-09-09 2019-01-15 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
EA201290575A1 (ru) 2010-01-15 2013-01-30 Джилид Сайэнс, Инк. Ингибиторы вирусов flaviviridae
TWI491609B (zh) * 2010-01-15 2015-07-11 Gilead Sciences Inc 黃熱病毒科(Flaviviridae)病毒之抑制劑類
TW201306841A (zh) * 2010-12-20 2013-02-16 Gilead Sciences Inc 治療c型肝炎病毒(hcv)之方法
DE102011003295A1 (de) * 2011-01-28 2012-08-02 Kiekert Ag Kraftfahrzeugschloss
US8741946B2 (en) 2011-07-13 2014-06-03 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
HRP20180237T4 (hr) * 2011-09-16 2020-12-11 Gilead Pharmasset Llc Metode za liječenje hcv-a
CN103087052A (zh) * 2011-10-31 2013-05-08 上海壹志医药科技有限公司 噻吩衍生物及其药物用途
SI2859009T1 (sl) 2012-06-08 2017-12-29 Gilead Sciences, Inc. Makrociklični inhibitorji flaviviridae virusov
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
IN2014MN02652A (enExample) 2012-06-08 2015-08-21 Gilead Sciences Inc
US8927741B2 (en) 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8759544B2 (en) * 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8841340B2 (en) * 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
US10190162B2 (en) 2014-10-23 2019-01-29 Complete Genomics, Inc. Signal confinement sequencing (SCS) and nucleotide analogues for signal confinement sequencing
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US10328061B2 (en) 2016-05-02 2019-06-25 Florida State University Research Foundation, Inc. Treatment of Zika virus infections using alpha-glucosidase inhibitors
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
CN108096562B (zh) * 2017-12-25 2021-05-11 武汉百药联科科技有限公司 20s蛋白酶体抑制剂在制备治疗日本乙型脑炎病毒感染的药物中的用途
EP4178955A1 (en) 2020-07-11 2023-05-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100851A2 (en) * 2001-06-11 2002-12-19 Shire Biochem Inc. Thiophene derivatives as antiviral agents for flavivirus infection
WO2005095386A1 (en) * 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
CN1795190A (zh) * 2002-12-10 2006-06-28 维勒凯姆制药股份有限公司 用于治疗或预防黄病毒感染的化合物及方法
CN101568538A (zh) * 2006-11-15 2009-10-28 Viro化学制药公司 用于治疗或预防黄病毒属感染的噻吩类似物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US743729A (en) * 1903-03-02 1903-11-10 William Clark Kirk Work-support for lathes.
US3533088A (en) * 1967-10-31 1970-10-06 Rca Corp Control circuit for memory
US4714839A (en) * 1986-03-27 1987-12-22 Advanced Micro Devices, Inc. Control circuit for disabling or enabling the provision of redundancy
US4721868A (en) * 1986-09-23 1988-01-26 Advanced Micro Devices, Inc. IC input circuitry programmable for realizing multiple functions from a single input
JPH02146195A (ja) * 1988-11-28 1990-06-05 Nec Corp 半導体記憶装置
JPH03214500A (ja) * 1990-01-18 1991-09-19 Sony Corp メモリ装置
JP2575919B2 (ja) * 1990-03-22 1997-01-29 株式会社東芝 半導体記憶装置の冗長回路
US5959445A (en) * 1995-09-29 1999-09-28 Intel Corporation Static, high-sensitivity, fuse-based storage cell
US5861421A (en) 1995-12-21 1999-01-19 Smithkline Beecham Corporation 4,4-(disubstituted) cyclohexan-1-one monomers and related compounds
US6037799A (en) * 1995-12-29 2000-03-14 Stmicroelectronics, Inc. Circuit and method for selecting a signal
US20050119332A1 (en) 1998-03-12 2005-06-02 Lone Jeppesen Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases)
US20020002199A1 (en) 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
US6175261B1 (en) * 1999-01-07 2001-01-16 Texas Instruments Incorporated Fuse cell for on-chip trimming
US6275063B1 (en) * 1999-08-24 2001-08-14 Micron Technology, Inc. Method and apparatus for limited reprogrammability of fuse options using one-time programmable elements
US6353336B1 (en) * 2000-03-24 2002-03-05 Cypress Semiconductor Corp. Electrical ID method for output driver
EP1395571A1 (en) 2001-06-11 2004-03-10 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
KR100481179B1 (ko) * 2002-09-10 2005-04-07 삼성전자주식회사 퓨즈를 구비한 회로 및 이를 이용한 반도체 장치
JP3884374B2 (ja) * 2002-12-06 2007-02-21 株式会社東芝 半導体装置
ATE466856T1 (de) 2002-12-10 2010-05-15 Virochem Pharma Inc Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen
KR100569585B1 (ko) * 2003-12-05 2006-04-10 주식회사 하이닉스반도체 내부 전원 드라이버 제어 회로
DE10359791A1 (de) 2003-12-19 2005-07-21 Bayer Healthcare Ag Substituierte Thiophene
WO2005081954A2 (en) 2004-02-25 2005-09-09 Wyeth Inhibitors of protein tyrosine phosphatase 1b
DE102004061746A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
DE102005028077A1 (de) 2004-12-22 2006-07-13 Aicuris Gmbh & Co. Kg Alkinyl-substituierte Thiophene
JP5030947B2 (ja) * 2005-05-13 2012-09-19 ヴァイロケム・ファーマ・インコーポレーテッド フラビウイルス感染の治療及び予防のための化合物及び方法
CN101501215A (zh) 2005-07-07 2009-08-05 阿什洛米克斯控股有限公司 用于诊断内毒素血症的多核苷酸标记基因及它们的表达
GB0602046D0 (en) 2006-02-01 2006-03-15 Smithkline Beecham Corp Compounds
AU2007214710A1 (en) 2006-02-15 2007-08-23 Sanofi-Aventis Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
ATE524465T1 (de) 2006-11-17 2011-09-15 Glaxosmithkline Llc 2-carboxy-thiophen-derivate als viruzide
WO2010065668A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
KR20120051022A (ko) * 2009-07-21 2012-05-21 길리애드 사이언시즈, 인코포레이티드 플라비비리데 바이러스의억제제
CA2771124C (en) 2009-09-09 2019-01-15 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
EP2504329A1 (en) 2009-11-25 2012-10-03 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
TWI491609B (zh) 2010-01-15 2015-07-11 Gilead Sciences Inc 黃熱病毒科(Flaviviridae)病毒之抑制劑類
EA201290575A1 (ru) * 2010-01-15 2013-01-30 Джилид Сайэнс, Инк. Ингибиторы вирусов flaviviridae
JP2013529684A (ja) 2010-06-28 2013-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染の処置または予防のための化合物および方法
US8741946B2 (en) 2011-07-13 2014-06-03 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100851A2 (en) * 2001-06-11 2002-12-19 Shire Biochem Inc. Thiophene derivatives as antiviral agents for flavivirus infection
CN1795190A (zh) * 2002-12-10 2006-06-28 维勒凯姆制药股份有限公司 用于治疗或预防黄病毒感染的化合物及方法
WO2005095386A1 (en) * 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
CN101568538A (zh) * 2006-11-15 2009-10-28 Viro化学制药公司 用于治疗或预防黄病毒属感染的噻吩类似物

Also Published As

Publication number Publication date
CR20120417A (es) 2012-11-30
PT2523950T (pt) 2017-06-01
SG182475A1 (en) 2012-08-30
US20130315861A1 (en) 2013-11-28
CL2012001960A1 (es) 2012-10-26
SI2523950T1 (sl) 2017-06-30
EP2523950A1 (en) 2012-11-21
US20110178129A1 (en) 2011-07-21
CN102712633A (zh) 2012-10-03
EP3219713A1 (en) 2017-09-20
WO2011088345A1 (en) 2011-07-21
US8513298B2 (en) 2013-08-20
EA201290576A1 (ru) 2013-01-30
PL2523950T3 (pl) 2017-09-29
EP2523950B1 (en) 2017-03-15
TWI491609B (zh) 2015-07-11
AR080001A1 (es) 2012-03-07
AU2011205744B2 (en) 2015-06-25
IL220545B (en) 2018-02-28
ZA201205248B (en) 2013-03-27
BR112012017382A2 (pt) 2017-12-05
AP3576A (en) 2016-02-08
US9321753B2 (en) 2016-04-26
KR20120101733A (ko) 2012-09-14
EA021196B1 (ru) 2015-04-30
SG10201500298PA (en) 2015-03-30
KR101727776B1 (ko) 2017-04-17
JP2016041732A (ja) 2016-03-31
NZ600817A (en) 2014-08-29
PE20130281A1 (es) 2013-03-08
IL220545A0 (en) 2012-08-30
AU2011205744A1 (en) 2012-07-26
ES2626150T3 (es) 2017-07-24
CA2785567C (en) 2018-03-27
TW201134822A (en) 2011-10-16
MX2012008211A (es) 2012-08-08
AP2012006414A0 (en) 2012-08-31
CA2785567A1 (en) 2011-07-21
ECSP12012104A (es) 2012-09-28
UY33183A (es) 2011-08-31
JP5868872B2 (ja) 2016-02-24
JP2013517291A (ja) 2013-05-16

Similar Documents

Publication Publication Date Title
US9321753B2 (en) Inhibitors of Flaviviridae viruses
US8884030B2 (en) Inhibitors of Flaviviridae viruses
ES2427342T3 (es) Ácidos 5-alquiniltien-2-ilcarboxílicos como inhibidores de virus de los Flaviviridae
US8501714B2 (en) Inhibitors of Flaviviridae viruses
HK1236521A1 (en) Inhibitors of flaviviridae viruses
HK1171444A (en) Inhibitors of flaviviridae viruses
HK1171444B (en) Inhibitors of flaviviridae viruses
AU2013202999A1 (en) Inhibitors of flaviviridae viruses
HK1171443B (en) Inhibitors of flaviviridae viruses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant